Literature DB >> 22086630

[Results of the implementation of three national guidelines for the prevention of HIV vertical transmission in Instituto Nacional Materno Perinatal. Lima, Peru].

Carlos Velásquez1.   

Abstract

A retrospective analysis is performed in three successive periods between the years 1996 and 2009, in order to evaluate the impact of the implementation of three national guidelines for the prevention of the vertical transmission of HIV. 275 births were included in 13 years. Significant statistical differences were found in the percentage of HIV cases in the children exposed to the virus between the three periods: 15% during the period in which only zidovudine (AZT) was administered to the pregnant woman, 6.4% during the second period (administration of AZT to the pregnant woman not fulfilling HAART initiation criteria and HAART to those fulfilling criteria for this treatment), and 4% during the third period in which HAART was applied to all pregnant women with HIV infection. 95% of pregnant women ended their pregnancy by cesarean section and the 100% of children received infant formula. Changes made in national guidelines have produced a positive impact in the decrease of HIV infected children in the Instituto Nacional Materno Perinatal in Peru.

Entities:  

Mesh:

Year:  2011        PMID: 22086630     DOI: 10.1590/s1726-46342011000300013

Source DB:  PubMed          Journal:  Rev Peru Med Exp Salud Publica        ISSN: 1726-4634


  2 in total

1.  Morbidity and Mortality of a Cohort of Peruvian HIV-infected Children 2003-2012.

Authors:  Amira N Baker; Angela M Bayer; Rolando M Viani; Lenka Kolevic; Myung-Shin Sim; Jaime G Deville
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 3.806

Review 2.  Experiences and Attitudes of People with HIV/AIDS: A Systematic Review of Qualitative Studies.

Authors:  Tomás Arias-Colmenero; Mª Ángeles Pérez-Morente; Antonio Jesús Ramos-Morcillo; Concepción Capilla-Díaz; María Ruzafa-Martínez; César Hueso-Montoro
Journal:  Int J Environ Res Public Health       Date:  2020-01-19       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.